NASDAQ:FIXX - Homology Medicines Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$16.19 -1.16 (-6.69 %)
(As of 08/19/2018 05:25 AM ET)
Previous Close$16.19
Today's Range$16.06 - $17.54
52-Week Range$15.22 - $24.40
Volume66,104 shs
Average Volume141,735 shs
Market Capitalization$581.93 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Homology Medicines logoHomology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities?gene editing and gene therapy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

Receive FIXX News and Ratings via Email

Sign-up to receive the latest news and ratings for FIXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FIXX
CUSIPN/A
Phone781-301-7277

Debt

Debt-to-Equity RatioN/A
Current Ratio12.75
Quick Ratio12.75

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees67
Outstanding Shares37,470,000
Market Cap$581.93 million

Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

How were Homology Medicines' earnings last quarter?

Homology Medicines Inc (NASDAQ:FIXX) issued its quarterly earnings results on Monday, August, 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.02. The firm had revenue of $0.93 million for the quarter. View Homology Medicines' Earnings History.

When is Homology Medicines' next earnings date?

Homology Medicines is scheduled to release their next quarterly earnings announcement on Monday, November, 12th 2018. View Earnings Estimates for Homology Medicines.

What price target have analysts set for FIXX?

4 brokers have issued 1 year price objectives for Homology Medicines' shares. Their predictions range from $27.00 to $35.00. On average, they expect Homology Medicines' share price to reach $30.6667 in the next year. This suggests a possible upside of 89.4% from the stock's current price. View Analyst Price Targets for Homology Medicines.

What is the consensus analysts' recommendation for Homology Medicines?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Homology Medicines.

Who are some of Homology Medicines' key competitors?

Who are Homology Medicines' key executives?

Homology Medicines' management team includes the folowing people:
  • Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 55)
  • Mr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 62)
  • Mr. Albert Seymour Ph.D., Chief Scientific Officer (Age 50)
  • Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory Board
  • Dr. Siyamak Rasty Ph.D., Chief Operating Officer (Age 54)

When did Homology Medicines IPO?

(FIXX) raised $100 million in an IPO on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

When does Homology Medicines' lock-up period expire?

Homology Medicines' lock-up period expires on Monday, September 24th. Homology Medicines had issued 9,000,000 shares in its IPO on March 28th. The total size of the offering was $144,000,000 based on an initial share price of $16.00. After the end of Homology Medicines' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Has Homology Medicines been receiving favorable news coverage?

Media headlines about FIXX stock have trended somewhat positive recently, according to Accern. Accern rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Homology Medicines earned a daily sentiment score of 0.12 on Accern's scale. They also assigned press coverage about the company an impact score of 45.89 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Homology Medicines.

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (8.97%), Vivo Capital LLC (3.76%), BlackRock Inc. (1.42%), Victory Capital Management Inc. (0.25%), Schwab Charles Investment Management Inc. (0.13%) and Bank of New York Mellon Corp (0.07%). Company insiders that own Homology Medicines stock include James E Flynn and Vida Ventures, Llc. View Institutional Ownership Trends for Homology Medicines.

Which institutional investors are selling Homology Medicines stock?

FIXX stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Bank of America Corp DE and Victory Capital Management Inc.. View Insider Buying and Selling for Homology Medicines.

Which institutional investors are buying Homology Medicines stock?

FIXX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Vivo Capital LLC, Schwab Charles Investment Management Inc. and Bank of New York Mellon Corp. Company insiders that have bought Homology Medicines stock in the last two years include James E Flynn and Vida Ventures, Llc. View Insider Buying and Selling for Homology Medicines.

How do I buy shares of Homology Medicines?

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $16.19.

How big of a company is Homology Medicines?

Homology Medicines has a market capitalization of $581.93 million. Homology Medicines employs 67 workers across the globe.

How can I contact Homology Medicines?

Homology Medicines' mailing address is 45 WIGGINS AVE., BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.


MarketBeat Community Rating for Homology Medicines (NASDAQ FIXX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  23 (Vote Outperform)
Underperform Votes:  13 (Vote Underperform)
Total Votes:  36
MarketBeat's community ratings are surveys of what our community members think about Homology Medicines and other stocks. Vote "Outperform" if you believe FIXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FIXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.